Early detection of diabetic kidney disease: Present limitations and future perspectives

Diabetic kidney disease (DKD) is one of the most common diabetic complications, as well as the leading cause of chronic kidney disease and end-stage renal disease around the world. To prevent the dreadful consequence, development of new assays for diagnostic of DKD has always been the priority in th...

Full description

Saved in:
Bibliographic Details
Published in:World journal of diabetes 2016-07, Vol.7 (14), p.290-301
Main Authors: Lin, Chih-Hung, Chang, Yi-Cheng, Chuang, Lee-Ming
Format: Article
Language:English
Subjects:
Biomarkers
Diabetic
diagnosis
Genomics
disease
Early
kidney
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetic kidney disease (DKD) is one of the most common diabetic complications, as well as the leading cause of chronic kidney disease and end-stage renal disease around the world. To prevent the dreadful consequence, development of new assays for diagnostic of DKD has always been the priority in the research field of diabetic complications. At present, urinary albumin-to-creatinine ratio and estimated glomerular filtration rate (eGFR) are the standard methods for assessing glomerular damage and renal function changes in clinical practice. However,due to diverse tissue involvement in different individuals,the so-called “non-albuminuric renal impairment” is not uncommon, especially in patients with type 2 diabetes.On the other hand, the precision of creatinine-based GFR estimates is limited in hyperfiltration status. These facts make albuminuria and eGFR less reliable indicators for early-stage DKD. In recent years, considerable progress has been made in the understanding of the pathogenesis of DKD, along with the elucidation of its genetic profiles and phenotypic expression of different molecules. With the help of ever-evolving technologies,it has gradually become plausible to apply the thriving information in clinical practice. The strength and weakness of several novel biomarkers, genomic, proteomic and metabolomic signatures in assisting the early diagnosis of DKD will be discussed in this article.
ISSN:1948-9358
1948-9358
DOI:10.4239/wjd.v7.i14.290